PeptideCompareAbaloparatide — EU research guide.
Abaloparatide is a synthetic 34-amino-acid analogue of PTHrP (parathyroid hormone-related protein) approved in the US as Tymlos for osteoporosis. It selectively activates PTH1R in the RG conformation, producing more anabolic bone effects than teriparatide.
What is Abaloparatide?
Abaloparatide selectively binds the RG (high-affinity) conformation of PTH1R rather than the RO conformation, producing more transient cAMP signalling and greater anabolic (bone-forming) versus catabolic (bone-resorbing) effects than teriparatide (PTH 1-34). It was approved by FDA in 2017 as Tymlos for postmenopausal osteoporosis with severe fracture risk.
What does the research show?
The ACTIVE trial showed superior vertebral fracture risk reduction versus placebo and non-inferior hip fracture reduction versus teriparatide. The anabolic window — the period of net bone formation — appears wider with abaloparatide due to its receptor binding selectivity. Research interest focuses on bone biology, PTH1R pharmacology and comparative anabolic mechanisms.
EU legal status
FDA-approved in the US (Tymlos) but not EMA-approved in the EU as of mid-2026. Research-grade abaloparatide is available from EU vendors for bone biology research. Not for human use without prescription in jurisdictions where it is approved.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Computed from molecular properties (sequence length, cyclisation, residues prone to oxidation or deamidation, light sensitivity), per compound. Indicative only — not lab-measured per batch.
Abaloparatide across EU suppliers
COA-verified EU vendors · Updated monthly
References
- The pivotal ACTIVE trial: 2,463 postmenopausal women received abaloparatide 80 mcg, placebo, or open-label teriparatide for 18 months — abaloparatide cut new vertebral fractures by 86% versus placebo, the basis for its 2017 FDA approval as Tymlos. Miller PD, et al. JAMA. 2016;316(7):722–733. DOIPubMed 27533157
- The ATOM trial extended the drug to men: 228 men with osteoporosis randomised 2:1 to abaloparatide or placebo for 12 months showed significant BMD gains at the spine, hip and femoral neck — the trial behind the 2022 FDA label expansion to male osteoporosis. Czerwinski E, et al. J Bone Miner Res. 2022;37(12):2435–2442. DOI